Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000989 | 0.86 | PARP1 (0.51) | ALDH1A1KDM4EMAPTHTR1ASLC6A4 | |
| SCHEMBL1001898 | 0.75 | PARP1 (0.49) | ACHEPARP1PARP2CCR3 | |
| SCHEMBL1003044 | 0.73 | PARP1 (0.53) | ALDH1A1KDM4EMAPTACHEPARP1 | |
| SCHEMBL8246354 | 0.72 | KDM4E (0.44) | ALDH1A1KDM4EMAPTACHEPARP1 | |
| SCHEMBL28801570 | 0.70 | SIGMAR1 (0.70) | ALDH1A1KDM4EMAPTACHESIGMAR1 | |
| SCHEMBL1001867 | 0.70 | MEN1 (0.46) | ACHEPARP1PARP2 | |
| SCHEMBL7375679 | 0.69 | SIGMAR1 (0.65) | ALDH1A1KDM4EMAPTHTR1ASLC6A4 | |
| SCHEMBL1003204 | 0.69 | PARP1 (0.51) | ALDH1A1ACHEPARP1PARP2SIGMAR1 | |
| SCHEMBL12013920 | 0.68 | SIGMAR1 (0.70) | ALDH1A1KDM4EMAPTACHESIGMAR1 | |
| SCHEMBL1002130 | 0.67 | PARP1 (0.50) | HTR1AACHEPARP1PARP2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | ALDH1A1 1757/4885KDM4E 3408/4885MAPT 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.